Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
[Cancer Research 48, 4024-4031, July 15, 1988]
© 1988 American Association for Cancer Research
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heinemann, V.
Right arrow Articles by Plunkett, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heinemann, V.
Right arrow Articles by Plunkett, W.

Comparison of the Cellular Pharmacokinetics and Toxicity of 2',2'-Difluorodeoxycytidine and 1-ß-D-Arabinofuranosylcytosine1

Volker Heinemann, Larry W. Hertel, Gerald B. Grindey and William Plunkett2

Department of Medical Oncology, The University of Texas, M. D. Anderson Hospital and Tumor Institute at Houston, Houston, Texas 77030 [V. H., W. P.], and Lilly Research Laboratories, Indianapolis, Indiana 46285 [L. W. H., G. B. G.]

2',2'-Difluorodeoxycytidine (dFdC) is a new deoxycytidine analogue with good activity against human leukemic cell lines and murine solid tumors, while the activity of 1-ß-D -arabinofuranosylcytosine (ara-C) is established in experimental systems and for the treatment of human adult leukemia. This study compared the cellular metabolism and cytotoxic properties of dFdC and ara-C in Chinese hamster ovary cells. In wild-type cells, dFdC was significantly more cytotoxic than ara-C after both 4- and 18-h incubations. The 5'-triphosphate of dFdC (dFdCTP) was the major cellular metabolite (85–90%), reaching cellular concentrations up to 20-fold greater than those observed for ara-C 5'-triphosphate at equimolar concentrations of the parent drug. A deoxycytidine kinase-deficient mutant neither accumulated dFdCTP nor showed any cytotoxic response up to drug concentrations of 100 µM. The cytotoxicity of dFdC could be competitively reversed by deoxycytidine further suggesting that dFdC, like ara-C, required phosphorylation by deoxycytidine kinase for biological activity. Several explanations for the different cellular accumulation of the drug triphosphates were established: (a) nucleoside transport studies demonstrated that the membrane permeation of dFdC was 65% more rapid than that of ara-C; (b) deoxycytidine kinase had a higher affinity for dFdC (Km = 3.6 µM) than for ara-C (Km = 8.8 µM), while the Km for deoxycytidine was 1.4 µM; (c) the elimination of intracellular dFdCTP was biphasic with tv2{alpha} = 3.9 and tv2ß > 16 h while the degradation of ara-CTP was monophasic and significantly faster (tv2 = 0.7 h). The comparatively long half-life of dFdCTP was related to the prolonged inhibition of DNA synthesis after removal of exogenous nucleoside. Together these factors contribute to the more potent cytotoxicity of dFdC compared with ara-C.

1 Supported by Grant CA28596 from the National Cancer Institute, Department of Health and Human Services, and Grant CH-130 from the American Cancer Society.

2 To whom requests for reprints should be addressed, at Department of Medical Oncology, The University of Texas, M. D. Anderson Hospital and Tumor Institute at Houston, 1515 Holcombe Blvd., Box 52, Houston, TX 77030.

Received 10/ 7/87. Revised 1/26/88. Revised 4/11/88. Accepted 4/14/88.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
L.-S. Tham, L. Wang, R. A. Soo, S.-C. Lee, H.-S. Lee, W.-P. Yong, B.-C. Goh, and N. H.G. Holford
A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non-Small Cell Lung Cancer Patients
Clin. Cancer Res., July 1, 2008; 14(13): 4213 - 4218.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. A. Veltkamp, R. S. Jansen, S. Callies, D. Pluim, C. M. Visseren-Grul, H. Rosing, S. Kloeker-Rhoades, V. A.M. Andre, J. H. Beijnen, C. A. Slapak, et al.
Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study
Clin. Cancer Res., June 1, 2008; 14(11): 3477 - 3486.
[Abstract] [Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
T. Yeo, J Kintner, R Armand, R Perez, and L. Lewis
Sublethal concentrations of gemcitabine (2',2'-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxPC-3 human pancreatic carcinoma cells
Human and Experimental Toxicology, December 1, 2007; 26(12): 911 - 921.
[Abstract] [PDF]

Home page
 The OncologistHome page
R. G. Maki
Gemcitabine and Docetaxel in Metastatic Sarcoma: Past, Present, and Future
Oncologist, August 1, 2007; 12(8): 999 - 1006.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. Murakami, H. Bao, M. Ramesh, T. R. McBrayer, T. Whitaker, H. M. Micolochick Steuer, R. F. Schinazi, L. J. Stuyver, A. Obikhod, M. J. Otto, et al.
Mechanism of Activation of {beta}-D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine and Inhibition of Hepatitis C Virus NS5B RNA Polymerase
Antimicrob. Agents Chemother., February 1, 2007; 51(2): 503 - 509.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. F. El-Rayes, S. Gadgeel, A. F. Shields, S. Manza, P. Lorusso, and P. A. Philip
Phase I Study of Bryostatin 1 and Gemcitabine
Clin. Cancer Res., December 1, 2006; 12(23): 7059 - 7062.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. A. Soo, L. Z. Wang, L. S. Tham, W. P. Yong, M. Boyer, H. L. Lim, H. S. Lee, M. Millward, S. Liang, P. Beale, et al.
A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer
Ann. Onc., July 1, 2006; 17(7): 1128 - 1133.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. P. Lee, M. J.A. de Jonge, A. E. O'Donnell, K. L. Schothorst, J. Hanwell, J. B. Chick, R. A. Brooimans, L. M. Adams, D. W. Drolet, J. S. de Bono, et al.
A Phase I Study of a New Nucleoside Analogue, OSI-7836, Using Two Administration Schedules in Patients with Advanced Solid Malignancies.
Clin. Cancer Res., May 1, 2006; 12(9): 2841 - 2848.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
J. Furuse, H. Ishii, T. Okusaka, M. Nagase, K. Nakachi, H. Ueno, M. Ikeda, C. Morizane, and M. Yoshino
Phase I Study of Fixed Dose Rate Infusion of Gemcitabine in Patients with Unresectable Pancreatic Cancer
Jpn. J. Clin. Oncol., December 1, 2005; 35(12): 733 - 738.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. M. Bergman, P. P. Eijk, V. W.T. Ruiz van Haperen, K. Smid, G. Veerman, I. Hubeek, P. van den IJssel, B. Ylstra, and G. J. Peters
In vivo Induction of Resistance to Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunit M1 as the Major Determinant
Cancer Res., October 15, 2005; 65(20): 9510 - 9516.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Matsui, T. Hirashima, T. Nitta, M. Kobayashi, Y. Ogata, M. Furukawa, S. Kudoh, N. Yoshimura, T. Mukohara, S. Yamauchi, et al.
A Phase I/II Study Comparing Regimen Schedules of Gemcitabine and Docetaxel in Japanese Patients with Stage IIIB/IV Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., April 1, 2005; 35(4): 181 - 187.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Yonemori, H. Ueno, T. Okusaka, N. Yamamoto, M. Ikeda, N. Saijo, T. Yoshida, H. Ishii, J. Furuse, E. Sugiyama, et al.
Severe Drug Toxicity Associated with a Single-Nucleotide Polymorphism of the Cytidine Deaminase Gene in a Japanese Cancer Patient Treated with Gemcitabine plus Cisplatin
Clin. Cancer Res., April 1, 2005; 11(7): 2620 - 2624.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. D. Erion, P. D. van Poelje, D. A. MacKenna, T. J. Colby, A. C. Montag, J. M. Fujitaki, D. L. Linemeyer, and D. A. Bullough
Liver-Targeted Drug Delivery Using HepDirect Prodrugs
J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 554 - 560.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. Pauwels, A. E.C. Korst, F. Lardon, and J. B. Vermorken
Combined Modality Therapy of Gemcitabine and Radiation
Oncologist, January 1, 2005; 10(1): 34 - 51.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. A. Huxham, A. H. Kyle, J. H. E. Baker, L. K. Nykilchuk, and A. I. Minchinton
Microregional Effects of Gemcitabine in HCT-116 Xenografts
Cancer Res., September 15, 2004; 64(18): 6537 - 6541.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. T. Milano, D. J. Haraf, K. M. Stenson, M. E. Witt, C. Eng, B. B. Mittal, A. Argiris, H. Pelzer, M. F. Kozloff, and E. E. Vokes
Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck
Clin. Cancer Res., August 1, 2004; 10(15): 4922 - 4932.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Reid, W. Qu, S. L. Safgren, M. M. Ames, M. D. Krailo, N. L. Seibel, J. Kuttesch, and J. Holcenberg
Phase I Trial and Pharmacokinetics of Gemcitabine in Children With Advanced Solid Tumors
J. Clin. Oncol., June 15, 2004; 22(12): 2445 - 2451.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. D. Davidson, L. Ma, M. Flagella, S. Geeganage, L. M. Gelbert, and C. A. Slapak
An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines
Cancer Res., June 1, 2004; 64(11): 3761 - 3766.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. M. De Lange, C. J. van Groeningen, J. R. Kroep, A. Van Bochove, J. F. Snijders, G. J. Peters, H. M. Pinedo, and G. Giaccone
Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer
Ann. Onc., March 1, 2004; 15(3): 484 - 488.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. R. Kroep, H. M. Pinedo, G. Giaccone, A. Van Bochove, G. J. Peters, and C. J. Van Groeningen
Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer
Ann. Onc., February 1, 2004; 15(2): 230 - 235.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. W. Robinson, M. M. Im, M. Ljungman, F. Praz, and D. S. Shewach
Enhanced Radiosensitization with Gemcitabine in Mismatch Repair-Deficient HCT116 Cells
Cancer Res., October 15, 2003; 63(20): 6935 - 6941.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Tempero, W. Plunkett, V. Ruiz van Haperen, J. Hainsworth, H. Hochster, R. Lenzi, and J. Abbruzzese
Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma
J. Clin. Oncol., September 15, 2003; 21(18): 3402 - 3408.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
M. Tiefenthaler, F. Hohla, E. Strasser-Wozak, N. Bacher, O. Muhlmann, W. Wein, and G. Konwalinka
Delayed Addition of Deoxycytidine Protects Normal CD34+ Cells against Cytotoxicity of Gemcitabine without Compromising Its Activity against Human Leukemic Cells
Stem Cells, May 1, 2003; 21(3): 266 - 271.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Pourquier, C. Gioffre, G. Kohlhagen, Y. Urasaki, F. Goldwasser, L. W. Hertel, S. Yu, R. T. Pon, W. H. Gmeiner, and Y. Pommier
Gemcitabine (2',2'-Difluoro-2'-Deoxycytidine), an Antimetabolite That Poisons Topoisomerase I
Clin. Cancer Res., August 1, 2002; 8(8): 2499 - 2504.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. R. Kroep, W. J. P. Loves, C. L. van der Wilt, E. Alvarez, I. Talianidis, E. Boven, B. J. M. Braakhuis, C. J. van Groeningen, H. M. Pinedo, and G. J. Peters
Pretreatment Deoxycytidine Kinase Levels Predict in Vivo Gemcitabine Sensitivity
Mol. Cancer Ther., April 1, 2002; 1(6): 371 - 376.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Gandhi, W. Plunkett, M. Du, M. Ayres, and E. H. Estey
Prolonged Infusion of Gemcitabine: Clinical and Pharmacodynamic Studies During a Phase I Trial in Relapsed Acute Myelogenous Leukemia
J. Clin. Oncol., February 1, 2002; 20(3): 665 - 673.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. P. Jung, M. V. Motwani, and G. K. Schwartz
Flavopiridol Increases Sensitization to Gemcitabine in Human Gastrointestinal Cancer Cell Lines and Correlates with Down-Regulation of Ribonucleotide Reductase M2 Subunit
Clin. Cancer Res., August 1, 2001; 7(8): 2527 - 2536.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. W. Robinson and D. S. Shewach
Radiosensitization by Gemcitabine in p53 Wild-Type and Mutant MCF-7 Breast Carcinoma Cell Lines
Clin. Cancer Res., August 1, 2001; 7(8): 2581 - 2589.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Eisbruch, D. S. Shewach, C. R. Bradford, J. F. Littles, T. N. Teknos, D. B. Chepeha, L. J. Marentette, J. E. Terrell, N. D. Hogikyan, L. A. Dawson, et al.
Radiation Concurrent With Gemcitabine for Locally Advanced Head and Neck Cancer: A Phase I Trial and Intracellular Drug Incorporation Study
J. Clin. Oncol., February 1, 2001; 19(3): 792 - 799.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. W. G. van Putten, H. J. M. Groen, K. Smid, G. J. Peters, and H. H. Kampinga
End-joining Deficiency and Radiosensitization Induced by Gemcitabine
Cancer Res., February 1, 2001; 61(4): 1585 - 1591.
[Abstract] [Full Text]

Home page
 Jpn J Clin OncolHome page
S. Okada, H. Ueno, T. Okusaka, M. Ikeda, J. Furuse, and Y. Maru
Phase I Trial of Gemcitabine in Patients with Advanced Pancreatic Cancer
Jpn. J. Clin. Oncol., January 1, 2001; 31(1): 7 - 12.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. J. Ostruszka and D. S. Shewach
The Role of Cell Cycle Progression in Radiosensitization by 2',2'-Difluoro-2'-deoxycytidine
Cancer Res., November 1, 2000; 60(21): 6080 - 6088.
[Abstract] [Full Text]

Home page
 JCOHome page
R. A. Nagourney, J. S. Link, J. B. Blitzer, C. Forsthoff, and S. S. Evans
Gemcitabine Plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Breast Cancer Patients
J. Clin. Oncol., June 11, 2000; 18(11): 2245 - 2249.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Haq, A. Shafii, E. E. Zervos, and A. S. Rosemurgy
Addition of Matrix Metalloproteinase Inhibition to Conventional Cytotoxic Therapy Reduces Tumor Implantation and Prolongs Survival in a Murine Model of Human Pancreatic Cancer
Cancer Res., June 1, 2000; 60(12): 3207 - 3211.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
Y.-G. Goan, B. Zhou, E. Hu, S. Mi, and Y. Yen
Overexpression of Ribonucleotide Reductase as a Mechanism of Resistance to 2,2-Difluorodeoxycytidine in the Human KB Cancer Cell Line
Cancer Res., September 1, 1999; 59(17): 4204 - 4207.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. L. Tonkinson, J. F. Worzalla, C.-H. Teng, and L. G. Mendelsohn
Cell Cycle Modulation by a Multitargeted Antifolate, LY231514, Increases the Cytotoxicity and Antitumor Activity of Gemcitabine in HT29 Colon Carcinoma
Cancer Res., August 1, 1999; 59(15): 3671 - 3676.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. W. Blackstock, S. A. Bernard, F. Richards, K. S. Eagle, L. D. Case, M. E. Poole, P. D. Savage, and J. E. Tepper
Phase I Trial of Twice-Weekly Gemcitabine and Concurrent Radiation in Patients With Advanced Pancreatic Cancer
J. Clin. Oncol., July 1, 1999; 17(7): 2208 - 2208.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. V. Iaffaioli, A. Tortoriello, G. Facchini, F. Caponigro, M. Gentile, N. Marzano, A. Gravina, P. Dimitri, G. Costagliola, A. Ferraro, et al.
Phase I-II Study of Gemcitabine and Carboplatin in Stage IIIB-IV Non–Small-Cell Lung Cancer
J. Clin. Oncol., March 1, 1999; 17(3): 921 - 921.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. R. Hammond, S. Lee, and P. J. Ferguson
[3H]Gemcitabine Uptake by Nucleoside Transporters in a Human Head and Neck Squamous Carcinoma Cell Line
J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1185 - 1191.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
L. Milas, T. Fujii, N. Hunter, M. Elshaikh, K. Mason, W. Plunkett, K. K. Ang, and W. Hittelman
Enhancement of Tumor Radioresponse in Vivo by Gemcitabine
Cancer Res., January 1, 1999; 59(1): 107 - 114.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. P. Gati, A. R.P. Paterson, L. M. Larratt, A. R. Turner, and A. R. Belch
Sensitivity of Acute Leukemia Cells to Cytarabine Is a Correlate of Cellular es Nucleoside Transporter Site Content Measured by Flow Cytometry With SAENTA-Fluorescein
Blood, July 1, 1997; 90(1): 346 - 353.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. J.A. van Moorsel, G. J. Peters, and H. M. Pinedo
Gemcitabine: Future Prospects of Single-Agent and Combination Studies
Oncologist, June 1, 1997; 2(3): 127 - 134.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Johansson and A. Karlsson
Cloning of the cDNA and Chromosome Localization of the Gene for Human Thymidine Kinase 2
J. Biol. Chem., March 28, 1997; 272(13): 8454 - 8458.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1988 by the American Association for Cancer Research.